Last updated: November 7, 2022
Sponsor: Saint Petersburg State University, Russia
Overall Status: Completed
Phase
3
Condition
Parathyroid Disease
Parathyroid Disorders
Bone Diseases
Treatment
N/AClinical Study ID
NCT04750460
TeriCa
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age > 18 years;
- Patients with end-stage renal disease (ESRD) receiving hemodialysis or peritonealdialysis treatment > 3 months prior surgery;
- Severe secondary hyperparathyroidism defined as iPTH level > 800 pg/ml, followed withhypercalcemia and/or hyperphosphatemia; with presence of one or more nodular ordiffuse parathyroid hyperplasia confirmed with CT;
- Performed total parathyroidectomy with autotransplantation of the parathyroid tissue.
Exclusion
Exclusion Criteria:
- Emergency surgery;
- Primary hyperparathyroidism as a cause of ESRD;
- Scheduled (before surgery) blood transfusion;
- Re-operative surgery;
- Known allergy to the study drug.
- Malignant neoplasms of bone tissue (primary or metastatic).
Study Design
Total Participants: 20
Study Start date:
March 01, 2021
Estimated Completion Date:
February 16, 2022
Study Description
Connect with a study center
Saint-Petersburg State University Hospital
Saint Petersburg, 190103
Russian FederationSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.